Kintara Therapeutics Inc Aktie News

TAMPA, Fla., 14. Sept. 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" oder das "Unternehmen"), ein im Phase-3-Bereich tätiges Immunonkologie-Unternehmen, das neuartige Therapeutika zur Überwindung von Resistenzen gegen Krebsimmuntherapie entwickelt, gab heute bekannt, dass die U.S. Food and Drug Administration (FDA) die Zulassung der Investigational New Drug (IND)-Anmeldu...

TAMPA, Fla., 14. Aug. 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" oder das "Unternehmen"), ein Unternehmen in Phase‑3 der Immunonkologie, das neuartige Therapeutika entwickelt, um Resistenzen gegen Krebsimmuntherapien zu überwinden, berichtete heute über die Finanzergebnisse des Unternehmens für das zweite Quartal zum 30. Juni 2026 und gab ein Unternehmensupdate.

The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML) The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed ...

TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.

TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A.

Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced th...

Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Amanda Garofalo, MSHS, as Senior Vice President (SVP) of Clinical...

TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's fourth quarter and full year ended December 31, 2025, and provided a corporate update.